Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
Giovanna Garufi, Antonella Palazzo, Ida Paris, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 6, pp. 687-699
Closed Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
Yang Li, Weigang Zhang, Yifeng Yan
Aging (2023) Vol. 15, Iss. 13, pp. 6135-6151
Open Access | Times Cited: 25
Structural Chromosome Instability: Types, Origins, Consequences, and Therapeutic Opportunities
Sebastián Omar Siri, J. Wise, Vanesa Gottifredi
Cancers (2021) Vol. 13, Iss. 12, pp. 3056-3056
Open Access | Times Cited: 47
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 37
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Guillermo Valencia, Patricia Rioja, Zaida Morante, et al.
World Journal of Clinical Oncology (2022) Vol. 13, Iss. 3, pp. 219-236
Open Access | Times Cited: 29
Guanosine diphosphate–mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer
Jia-Han Ding, Yi Xiao, Fan Yang, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 728
Closed Access | Times Cited: 6
The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production
Chun‐Ming Chang, Ting-Ruei Liang, Ho Yin Pekkle Lam
Biomolecules (2024) Vol. 14, Iss. 1, pp. 74-74
Open Access | Times Cited: 6
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies
Ombretta Melaiu, Gianluca Vanni, Ilaria Portarena, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3226-3226
Open Access | Times Cited: 14
Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model
Xu Han, Na Zhao, Wenwen Zhu, et al.
Cellular Immunology (2021) Vol. 368, pp. 104423-104423
Closed Access | Times Cited: 32
Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations
Ming D. Li, Shuling Zhou, Hong Lv, et al.
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access
PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
Haiying Zhu, Chengyong Du, Meng Yuan, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 9, pp. 1762-1771
Closed Access | Times Cited: 29
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer
Frederick M. Howard, Dario Martin Villamar, Gong He, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 531-548
Open Access | Times Cited: 26
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
Tara Hyder, Saveri Bhattacharya, Kristine Gade, et al.
Breast Cancer Targets and Therapy (2021) Vol. Volume 13, pp. 199-211
Open Access | Times Cited: 24
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Nusayba A. Bagegni, Andrew A. Davis, Katherine Clifton, et al.
Breast Cancer Targets and Therapy (2022) Vol. Volume 14, pp. 113-123
Open Access | Times Cited: 18
Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
Giovanna Garufi, Luisa Carbognin, Francesco Schettini, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4064-4064
Open Access | Times Cited: 16
New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
Brahim El Hejjioui, Salma Lamrabet, Sarah Amrani Joutei, et al.
Diagnostics (2023) Vol. 13, Iss. 11, pp. 1949-1949
Open Access | Times Cited: 9
The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy
Andrea Nicolini, Paola Ferrari, Roberto Silvestri, et al.
Journal of the National Cancer Center (2024) Vol. 4, Iss. 1, pp. 14-24
Open Access | Times Cited: 2
A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus
Rendong Zhang, Qiongzhi Jiang, Zhemin Zhuang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
RHAMM regulates MMTV-PyMT-induced lung metastasis by connecting STING-dependent DNA damage sensing to interferon/STAT1 pro-apoptosis signaling
Cornelia Tölg, Maja Milojevic, Freda Qi, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
Daniele Marinelli, Marco Mazzotta, Laura Pizzuti, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2497-2497
Open Access | Times Cited: 17
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing
Fan Yang, Kaige Deng, Haoran Zheng, et al.
Annals of Hepatology (2022) Vol. 27, Iss. 2, pp. 100677-100677
Open Access | Times Cited: 9
Socioeconomic and racial disparities in survival for patients with stage IV cancer
Kristen Jogerst, Chi Zhang, Yu‐Hui Chang, et al.
The American Journal of Surgery (2023) Vol. 226, Iss. 1, pp. 20-27
Closed Access | Times Cited: 5
Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
Meghavi Kathpalia, Anurag Sharma, Navkiran Kaur
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 1, pp. 44-53
Closed Access | Times Cited: 5
Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
Xiaoyu Zhang, Huixin Li, Feng Wu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-6
Open Access | Times Cited: 8
AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
Bi Meng, Xuan Zhao, Shuchang Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial
Ana Julia Aguiar de Freitas, C.R. Nunes, Max S. Mano, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top